# SPRO — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-07-15. Informational only, not financial advice.

**Recommendation:** ACCUMULATE

**Scores (0–100):** Overall 5.8 · Fundamentals 6 · Technicals 3 · Growth 7.5 · Risk 8

## Summary

Spero Therapeutics just crashed ~20% in 24h and ~37% over the past month, but the drop coincides with a transformative pivot: FDA approval of Utebzi (tebipenem), a $105M non-dilutive royalty deal with HealthCare Royalty/KKR, and an in-license of Innovent's CD40L antibody IBI355/SP001 for up to $1.1B in milestones. Fundamentals are unusually clean for a micro-cap biotech (net cash, $56M cash vs $2.5M debt, TTM profit from milestone recognition), but the sell-off reflects dilution/execution fears around the Innovent deal and a shift back to clinical-stage cash burn. At $1.70 with an analyst target of $4.00 and RSI 28, risk/reward skews favorably for patient capital, but near-term technicals remain broken.

## Price targets (12-month horizon)

- Bear: $0.90
- Base: $2.60
- Bull: $4.00

## News context

The signal-to-noise ratio in the news is high and mostly constructive despite the tape. Three linked July 14 catalysts: (1) FDA approval of Utebzi (tebipenem pivoxil) — a first-in-class oral carbapenem for cUTI partnered with GSK, which triggers royalty economics; (2) a $105M non-recourse, non-dilutive royalty financing with HealthCare Royalty (KKR affiliate) monetizing those future royalties; (3) an ex-China global license from Innovent for IBI355/SP001, a CD40L antibody entering Phase 2 in immunology, with up to $1.1B in milestones payable by Spero. The 8-K filed under Items 1.01/2.03/7.01/8.01 confirms material long-term obligations. The market clearly read the combination as 'Spero just sold its cash cow to bet on an unproven Phase 2 asset,' hence the -20% day. Seeking Alpha's 'Buy' framing and the pivot to immunology are the bull narrative. The L1 short-float uptick (4.3% → 6.7%) confirms a growing bear thesis; stocktwits sentiment is 100% bullish among tagged messages, which is contrarian-negative in a retail micro-cap.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/spro-ai-stock-forecast-c3896829c662be1f6a08e72c2c85931d
- AI-generated; model outputs can be wrong. Not financial advice.